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Severe injection site reactions after subcutane-
ous administration of Sayana®: a retrospective, 
post-marketing analysis of WHO and Swiss 
spontaneous pharmacovigilance reports 
Annika Jödicke Hendrike Dahmke Beat Damke Martina Schäublin Gerd A. Kullak-Ublick Stefan Weiler
Summary 
PURPOSE: Sayana® was introduced as the first depot 
medroxyprogesterone acetate-containing contraceptive 
that is administered via subcutaneous injection. Within 
10 months, the Regional Pharmacovigilance Centre 
(RPVC) Zurich received several anonymous reports of se-
rious local reactions after Sayana® administration. In this 
retrospective study, individual case safety reports 
(ICSRs) on local adverse drug reactions (ADRs) related to 
Sayana® were analysed from the WHO pharmacovigi-
lance database. 
METHODS: International, national and regional ICSRs 
during Sayana® administration up to 1 January 2016 
were examined. Data on ADRs were retrieved from the 
WHO Global Database VigiBase™. Demographic data, 
drug administration information, duration of Sayana® 
treatment, latency time of the ADR, and its course, se-
verity and outcomes were analysed. 
RESULTS: Worldwide, 398 ICSRs after Sayana® use were 
registered in the database. We identified 20 reported 
terms that were potentially used to describe a persistent 
lipodystrophy. When only cases containing one or more 
of these 20 reported terms were selected, 323 (81.2%) 
international ICSRs remained for analysis. Of those, 
91.6% (n = 296) were categorised as serious. The major-
ity of the reactions (n = 193, 54.4%) did not recover. In 
the 67 Swiss ICSRs, 77 ADRs were reported using 10 dif-
ferent terms including severe or persistent local reac-
tions like lipodystrophy, atrophy or fat necrosis. Thirty-
two patients (47.7%) did not recover. All 11 regional 
cases reported to the RPVC Zurich were categorised as 
serious ADRs. For the majority of the patients (n = 7, 
63.6%) the interval between the application of Sayana® 
and development of the lipodystrophy was between 2 
and 4 months. Most of the reactions were irreversible (n 
= 9, 81.8%). One patient underwent plastic surgery for 
artificial infill of the dent. 
CONCLUSIONS: Persistent local injection site reactions 
such as lipodystrophy, fat tissue necrosis or atrophy oc-
cur frequently after subcutaneous Sayana® use. These 
adverse drug reactions were recently integrated in the 
Swiss product information. Physicians and patients 
should be informed and advised about these potentially 
irreversible effects. 
Key words: adverse drug reaction; lipodystrophy; sub-
cutaneous contraception; depot medroxprogesterone 
acetate; VigiBase 
  
 Abbreviations 
ADR: adverse drug reaction 
DMPA: depot medroxprogesterone acetate 
DMPA-IM: intramuscularly injected depot medroxprogesterone ace-
tate 
DMPA-SC: subcutaneously injected depot medroxprogesterone ace-
tate 
ICSR: individual case safety report 
RPVC: Regional Pharmacovigilance Centre 
WHO: World Health Organization 
Introduction 
Depot medroxyprogesterone acetate (DMPA) injec-
tions have been effectively used for hormonal con-
traception for many years. The active ingredient in-
hibits the hypothalamus-hypophysis-gonad axis and 
therefore prevents ovulation and follicular matura-
tion [1, 2]. It is considered a safe method of paren-
teral contraception [3]. 
In the past, DMPA was given as an intramuscular 
injection and administered by health professionals 
only. The introduction of Sayana® to the Swiss mar-
ket on 5 April 2012 [4] provided a micronised 
DMPA formulation allowing subcutaneous injec-
tion (DMPA-SC). After administration, its contra-
ceptive effect lasts for 3 months. It is dispensed in a 
prefilled syringe with a DMPA concentration of 104 
mg in 0.65 ml, allowing self-administration by the 
patient into the subcutis of the thigh or abdominal 
wall. 
In clinical trials, injection site reactions were re-
ported as frequent adverse drug reactions (ADRs) 
[5, 6]. Within 10 months, the Regional Pharma-
covigilance Centre (RPVC) Zurich received 11 re-
ports of severe and persistent injection site reac-
tions, after administration of subcutaneous Sayana®. 
Therefore, we analysed data on international and 
Swiss spontaneous pharmacovigilance reports in the 
World Health Organization (WHO) pharmacovigi-
lance database Vigibase™. 
Methods 
Study design 
This retrospective descriptive study was based on 
selected individual case safety reports (ICSRs) from 
the WHO global database VigiBase™ and a sub-
group analysis of Swiss ICSRs. For more detailed 
data, we analysed the case series of 11 reports of 
ADRs issued to the RPVC of Zurich in 2014 and 
2015. 
VigiBase™ data 
VigiBase™ was established in 1968 within the 
WHO Programme for International Drug Monitor-
ing and is run by the Uppsala Monitoring Centre in 
Sweden [7]. In January 2016 it contained more than 
12.3 million ICSRs from 125 participating coun-
tries. An ICSR is an anonymised report for a single 
individual who suffered from one or more adverse 
events that may be linked to the use of one or more 
drugs. Since VigiBase™ is a register database, the 
international ICSRs contain neither narrative nor 
clinical or laboratory data. All ADRs are coded ac-
cording to the reported term as well as to the WHO 
Adverse Reaction Terminology (WHO-ART) and 
the Medical Dictionary for Regulatory Activities 
(MedDRA). In order to receive information most 
closely related to the actual adverse event, original 
reported terms were used for our analysis. 
We received the coded data elements of all interna-
tional Sayana®-associated ICSRs from the WHO 
global database VigiBase™ as a Microsoft Excel 
file via VigiLyze™. The case selection process is 
illustrated in figure 1. All reported terms were dis-
cussed independently by two pharmacists and one 
clinical pharmacologist, to determine if they could 
be used to describe a persistent injection site reac-
tion, comparable to those reported to the RPVC Zur-
ich. Twenty reported terms were regarded as rele-
vant and the corresponding ICSRs were selected for 
further study. From the selected ICSRs, a subgroup 
containing only ICSRs from Switzerland was 
formed. Both data sets were analysed for demo-
graphic data such as age at ADR onset and gender, 
completeness, reported ADR, outcome, concomi-
tant drugs, seriousness and seriousness criteria. The 
adverse reactions were classified as “severe” owing 
to the persistence of the condition of lipodystrophy 
and tissue damage. 
Regional data 
In Switzerland, ADRs are reported by both 
healthcare professionals and consumers to one of 
six RPVCs. These centres perform a causality as-
sessment according to WHO/CIOMS (Council for 
International Organizations of Medical Sciences) 
criteria and forward the reports to the Swissmedic 
National Pharmacovigilance Centre. To categorise 
the causality between drug exposure and ADR as 
“certain”, the following criteria must be fulfilled: 
plausible time relationship to drug intake, plausible 
response to withdrawal, no alternative explanation 
by disease or other drugs and a positive rechallenge. 
A rechallenge is considered positive if the patients 
show the same ADR after exposure to the suspected 
drug for a second time. Adverse reactions filed by 
the pharmaceutical industry are reported directly to 
Swissmedic. The National Pharmacovigilance Cen-
tre collaborates with the International Centre for 
 Drug Safety run by the WHO in Uppsala, Sweden 
[8]. 
Between June 2014 and April 2015, the RPVC Zur-
ich received 11 reports of injection site lipodystro-
phy after subcutaneous Sayana® injection. In order 
to obtain complete case reports, as well as supple-
mentary information and up-to-date follow-up in-
formation, the reporting physicians were contacted 
by the investigators. Data were analysed for age, in-
dication and first-line therapy, previous contracep-
tion, the person using the prefilled syringe, the num-
ber of applications until the ADR onset, number of 
applications in total, the localisation and extent of 
persistent local reactions, rechallenge, latency time, 
treatment of ADR, outcome and causality assess-
ments. 
 
Figure 1: Case selection process: all individual case safety reports (ICRSs) up to 1 January 2016. 
 
 Statistical analysis 
We performed descriptive analysis using Microsoft 
Office Excel (2010) and SPSS for Windows soft-
ware (version 22). For variables with normally dis-
tributed numeric values, the arithmetic mean and 
standard deviation were calculated. For variables 
without normally distributed values, median and 
range were determined. 
Results 
In the global database from the WHO VigiBase™ 
we identified 398 ICSRs for Sayana® up to 1 Janu-
ary 2016. A total of 620 ADRs were reported and 
174 different reported terms were used. After ex-
cluding all cases not likely to be related to a persis-
tent local reaction, 20 reported terms corresponding 
to 323 (81.2%) ICSRs remained for analysis. 
All selected reported terms are listed together with 
their frequency and the outcome of the reaction in 
table 1. A total of 355 reported terms were used. The 
most frequently reported term was “injection site re-
action” (n = 249, 70.1%) without further specifica-
tion, followed by “injection site atrophy” (n = 29, 
8.2%) and “injection site fat necrosis” (n = 15, 
4.2%). The majority of the reactions (n = 193, 
54.4%) did not recover; for 134 reactions (37.7%) 
the outcome was not reported. Of the 355 reported 
terms, only 1 (0.3%) was described as “recovered”. 
 
 
Table 1: Reported terms and outcome of adverse drug reactions corresponding to 323 international individual case safety reports. 
Reported terms Number Outcome 
Not recovered Recovered Recovered with sequelae Recovering Unknown 
Atrophy 2 2 0 0 0 0 
Atrophy injection site 7 3 0 0 1 3 
Atrophy skin 1 1 0 0 0 0 
Dellen 1 0 0 1 0 0 
Fat necrosis 1 0 0 1 0 0 
Injection site atrophy 29 18 0 5 0 6 
Injection site erosion 1 1 0 0 0 0 
Injection site fat atrophy 5 1 0 0 1 3 
Injection site fat necrosis 15 10 0 1 1 3 
Injection site induration 11 4 0 0 1 6 
Injection site lump 2 1 0 1 0 0 
Injection site necrosis 4 2 0 2 0 0 
Injection site reaction 249 131 0 9 1 108 
Injection site reaction NOS 2 2 0 0 0 0 
Injection site subcutaneous fat de-
creased 
1 1 0 0 0 0 
Lipoatrophy injection site 10 7 0 0 0 3 
Lipodystrophy 4 3 0 0 0 1 
Necrosis injection site 2 0 0 2 0 0 
Partial lipodystrophy 7 6 1 0 0 0 
Skin reaction localised 1 0 0 0 0 1 
Total 355 193 1 22 5 134 
NOS = not otherwise specified 
 The selected 323 ICSRs were analysed for com-
pleteness, sex, age at onset, monotherapy and seri-
ousness criteria (table 2). A total of 321 (99.4%) pa-
tients were female. The median age was 34 years 
(range 6–53 years). The average completeness score 
of the ICSRs was 0.35 (range 0.11–1). For most pa-
tients (n = 313, 96.9%), Sayana® was the only re-
ported drug; the most frequently used concomitant 
drug was levothyroxine (n = 5, 1.5%). However, 
none of the concomitant drugs were administered 
subcutaneously. Overall, 91.6% (n = 296) of the 
cases related to local reactions were categorised as 
serious (only 8.1% were categorised as nonserious). 
The seriousness criteria were “caused/prolonged 
hospitalisation, other” (n = 2, 0.6%), “disabling/in-
capacitating” (n = 9, 2.8%) and “disabling/incapac-
itating, other” (n = 7, 2.2%). For the majority of the 
cases, reasons for the classification as serious was 
not further detailed (“other” [n = 278, 86.1%]). 
 
Table 2: Characteristics of the individual case safety reports. 
 
International 
(n = 323) 
Switzerland 
(n = 67) 
Regional 
(n = 11) 
Characteristics Frequency Percent Frequency Percent Frequency Percent 
Sex female 321 99.4 66 98.5 11 100 
Sex unknown 2 0.6 1 1.5 0 0 
Completeness score, median (range) 0.35 
(0.11–1) 
 
0.28 
(0.11–1) 
 
0.90 
(0.32–1) 
 
Age at onset (years), median (range) 34 
(6–53) 
 
34 
(18–53) 
 
33 
(24–50) 
 
Monotherapy Sayana® 313 96.9 67 100 11 100 
Serious 296 91.6 64 95.5 11 100 
Seriousness criteria: 
      
Caused/prolonged hospitalisation, other 2 0.6 0 0 0 0 
Disabling/incapacitating 9 2.8 4 6 3 27.3 
Disabling/incapacitating, other 7 2.2 3 4.5 2 18.2 
Other 278 86.1 57 85.1 6 54.6 
 
 
Figure 2 shows the countries of origin of the reports, 
stratified by the reporter’s qualification. Most re-
ports were from Austria (n = 137, 42.4%), followed 
by Switzerland (n = 67, 20.7%) and Germany (n = 
58, 18.0%). In total, 80.1% of the reports came from 
German-speaking countries. In the vast majority of 
ICSRs, physicians were involved in the reporting 
(88.2%), either as the only reporter or in combina-
tion with others. Only 7.1% were reported by other 
healthcare professionals and 2.8% by con-
sumer/non-healthcare professionals. 
In the selected 67 Swiss ICSRs, 77 ADRs were re-
ported using 10 different terms including persistent 
local reactions such as lipodystrophy, atrophy or fat 
necrosis. The majority (n = 64, 95.5%) of the cases 
were categorised as serious. Only one patient recov-
ered, 32 did not recover and for 40 ADRs the out-
come was not reported. In these cases, the complete-
ness score was lower than the international average 
(0.28, range 0.11–1). The median age was the same 
as in the international data (34 years, range 18–53 
years). In all Swiss cases, Sayana® was adminis-
tered as monotherapy. 
The 11 cases were reported to the RPVC Zurich by 
six different physicians. The mean completeness 
score of regional ICSRs was higher at 0.90 (range 
0.32–1.00). All patients were female and aged be-
tween 24 and 50 years (median 33 years). For 10 out 
of 11 patients, the indication for the use of Sayana® 
was contraception. Information on the patients’ 
weight was available for two cases, with both pa-
tients being normal weight. For all patients, the pre-
vious method of contraception could be evaluated: 
five had received another progestin-only depot con-
traceptive, which was injected intramuscularly 
every 3 months, another five patients took oral con-
traceptives and one used a hormonal contraceptive 
for vaginal administration. For three patients, Sa-
yana® injections were administered by their physi-
cian, one patient performed the injections herself, 
and for seven patients the injections were given by 
medical practice assistants. 
  
 
Figure 2: Number of individual safety reports stratified by country of origin and reporters’ qualifications. 
 
In 4 of the 11 cases (36.4%), the lipodystrophy was 
already observed after the first injection of Sayana®; 
another 5 patients had two injections before the 
ADR was noticed. The latency between the injec-
tion of Sayana® and the development of lipodystro-
phy at the injection site ranged from several days up 
to 5 months. For the majority of the patients (n = 8, 
72.7%) the latency was 2–4 months. At least seven 
patients received an additional injection after the lo-
cal ADR. For one patient the “dents” on the thighs 
were noticed, but not linked to the drug administra-
tion. 
According to causality assessments by the RPVC, 
the causality was “certain” in six cases; for the other 
five cases the causality was “probable”. In seven 
cases, rechallenge was positive. The site of admin-
istration was changed from the thigh to the ab-
dominal wall in three cases; for the other four pa-
tients the location was changed on the thighs. In two 
patients the change of the injection sites from the 
thigh to the abdominal wall led to a negative rechal-
lenge. Two patients, who had no difficulties with 
previous injections, developed lipodystrophies after 
the second and the third application, respectively. 
Longitudinal data with follow-up of up to 17 
months after the initial report showed in 10 of the 
11 cases no amelioration, but persistence of the lo-
cal reaction. In one patient the “dent” was observa-
ble through her clothes. Another patient underwent 
plastic surgery for artificial infill of the affected 
area. The result of the injection of autologous fat 
was reported to be “satisfactory”. 
Discussion 
In this retrospective study both international and 
Swiss pharmacovigilance data regarding severe in-
jection site “dents” due to subcutaneous Sayana® 
administration were analysed. Additional qualita-
tive aspects, such as latency time and follow-up in-
formation, were provided by exploring the 11 re-
gional cases of persistent injection site fat tissue de-
struction. 
“Injection site reaction” is a very nonspecific ex-
pression often used as an umbrella term for the en-
coding of local ADRs. It covers a wide range of re-
actions: both severe cases of fat tissue destruction 
and also mild, transient conditions such as skin red-
ness, administration site pain, itchiness or swelling. 
The latter reactions are very well documented and 
frequently reported for locally administered drugs. 
Terms that may cover severe tissue destruction, 
such as atrophy or necrosis, have been extracted 
from the reported terms. Since Sayana® is the only 
subcutaneously administered DMPA preparation in 
Switzerland, we did not include other DMPA for-
mulations used in other countries into our analyses. 
In 313 patients Sayana® was administered as mono-
therapy. All patients with comedications received 
Sayana® as the only subcutaneously administered 
drug. Hence, the injection site reactions cannot be 
imputed to the comedication. 
Injection site reactions have been reported to be one 
of the most common reasons for discontinuation of 
therapy with DMPA-SC in the United States [9]. In 
two open-label phase III trials, Jain et al. assessed 
 the safety of DMPA-SC (104 mg / 0.65 ml) for a pe-
riod of 1 year. Nonallergic injection site reactions 
were reported in 1.6% of women taking part in the 
European/Asian trial and in 9.7% of the women in 
the American trial. The most common injection site 
reactions were described as injection site pain, gran-
uloma or atrophy and were reported to be mild in 
intensity for most of the cases [10]. In a prospective 
case series, 11 of 50 patients (22%) experienced in-
jection site reactions, with 3 patients (6%) develop-
ing a “dent” or “dimple” [6]. However, in these 
studies further information regarding reversibility 
or persistency of the reactions were not available. 
According to Prabhakaran et al., further observation 
regarding the lasting effects of the granulomas and 
atrophies was needed [6]. 
Out of our selected subset of 323 ICSRs, 296 ICSRs 
(91.6%) were classified as “serious”. Also, all 11 re-
gional ICSRs were classified as serious owing to 
persistent localised atrophy, fat tissue necrosis or 
lipodystrophy. In 10 of the 11 regional cases the 
condition had been present for almost a year and 
therefore seems to be irreversible. In one patient, the 
affected area could even be seen through clothes. 
Another patient underwent plastic surgery to re-
place necrotic tissue. This action illustrates the se-
verity of the situation for the affected patients. Con-
sequently, this aspect was also emphasised by the 
primary reporters of these ADRs. 
Since the mean latency time between exposure (sub-
cutaneous injection) and detection of the dent was 
found to be between 2 and 4 months, in some pa-
tients the tissue atrophy was initially not linked to 
the drug injection. Therefore, some women received 
another injection after the event. 
The reasons for the occurrence of lipodystrophy af-
ter Sayana® injections remain speculative. In none 
of the cases was a histological examination per-
formed. For the intramuscular administration of 
Depo-Provera® only injection site swelling and skin 
colour changes at the administration site are labelled 
as ADRs in the Swiss product information [11]. In-
jection site reactions occurred in 8% of the partici-
pants who used DMPA-SC in contrast to only 0.4% 
for the DMPA-IM users in a randomized clinical 
study carried out by Kaunitz et al. [12]. Dorai et al. 
have shown in in-vitro studies that synthetic proges-
tins such as medroxyprogesterone acetate show di-
rect lipolytic activity on adipocytes [13]. Since adi-
pocytes are abundant in the subcutaneous tissue, in 
contrast to the muscular tissue, a possible lipolytic 
effect cannot be ruled out [5]. Overweight or under-
weight as potential risk factors could not be ana-
lysed, since information regarding the patients’ 
body mass index was not available in most cases. 
The intramuscular formulation of DMPA contains 
150 mg / 1ml versus 104 mg / 0.65 ml for the sub-
cutaneous preparation [11]. This results in an over-
all lower dose, but a higher concentration for the 
subcutaneous compared with the intramuscular 
preparation. Aside from having the same active in-
gredient, there are slight differences in the compo-
sition of the excipients in the intramuscular and sub-
cutaneous formulations. In addition to macrogol 
3350, polysorbate 80, sodium chloride and water for 
injection, the subcutaneous preparation contains a 
sodium-phosphate-buffer. The amino acid methio-
nine and povidone are additional ingredients [2, 11]. 
Both formulations contain propylparahydroxyben-
zoate (E216) and methylparahydroxybenzoate 
(E218) as preserving agents, with a slightly higher 
concentration of the latter in the subcutaneous prep-
aration (1.6 mg/ml vs 1.35 mg/ml for E218; 0.154 
mg/ml vs 0.15 mg/ml for E216) [2, 11]. 
In a pilot study on self-administration of subcutane-
ous DMPA for contraception, 19 of 64 women 
(29.6%) were reported to have experienced difficul-
ties in connection with the injection process [5]. All 
patients had received injection training before they 
performed the self-administration. Atrophy, indura-
tion and scarring were described in five patients. 
These conditions occurred most commonly after the 
second injection. Follow-up until the end of the 
study showed that one reaction had resolved, two 
were reported to be almost resolved, another two as 
ongoing. One case was lost to follow-up [5]. In the 
study of Prabhakaran et al. 12 of 50 patients (24%) 
experienced plunger resistance during their initial 
self-injection and in 17% of all injections device or 
plunger issues were reported [6]. This might indi-
cate that, even with previous training, the admin-
istration process may be challenging for some 
women. In the regional case series, only one patient 
performed a self-injection and 10 received the injec-
tion either from a medical practice assistant or from 
their physician. Therefore, self-administration by 
laypeople might play only a minor role as a risk fac-
tor for these irreversible injection site reactions. 
Since most administrations were performed by 
medical professionals, insufficient disinfection of 
the administration site or contamination of the nee-
dle are possible, but unlikely. No injection site in-
fection or quality issues regarding the product have 
been reported for the regional cases. The Swiss 
product information of Sayana® now labels injec-
tion site reactions, including persistent atrophy or 
 lipodystrophy such as the occurrence of dents, nod-
ules or dimples, as common adverse reactions [2]. 
Although injection site atrophy and the develop-
ment of a “dent” or “dimple” has been observed in 
trials with subcutaneous DMPA [5, 6], to our 
knowledge, no post-marketing cases have been pub-
lished so far. 
A commonly described limitation in pharmacovigi-
lance is the underreporting of ADRs in a spontane-
ous reporting system, which amounts to up to 94% 
[14]. The intensity of injection site reactions can 
vary between mild and severe and the size of the af-
fected area may differ. Milder cases may not have 
been reported. As a result of the long latency time, 
the association of the event with the previous injec-
tion might not be obvious. Serious ADRs must be 
reported by law. However, a persistent dent at the 
site of injection might be subjectively assessed by 
the attending physician. Since “injection site reac-
tion” is a very nonspecific term and no validation of 
the coding was possible, ICSRs that are not related 
to lipodystrophy, atrophy, fat tissue necrosis may 
have been included in our analysis. However, 
91.6% of theses ICSRs were reported as serious. 
Completeness of documentation of the ICSRs was 
not homogenous. ICSRs included in the WHO data-
base had less information, as reflected by complete-
ness scores. In addition, follow-up information was 
often lacking. Therefore, regional cases, with exten-
sive information, causality assessment and longitu-
dinal follow-up information were included to im-
prove quality. In the WHO database, a causal rela-
tionship between drug and ADR could not be for-
mally assessed, and coding or recoding could not be 
verified. 
Conclusion 
Administration site reactions during subcutaneous 
DMPA treatment occur frequently. The evaluation 
of the ICSRs in the WHO databank and regional 
cases demonstrate severe tissue damage at the injec-
tion site. These reactions include local lipodystro-
phy and persistent atrophy occurring several weeks 
to months after subcutaneous injection. These 
ADRs were recently integrated in the Swiss product 
information of Sayana®. Since these adverse effects 
can be a substantial burden for the young patients, 
physicians should be aware of them and include this 
information into their risk-benefit assessment for in-
dividual patients. Patients should also be informed 
and advised about these recently labelled and poten-
tially irreversible adverse drug reactions at the in-
jection site. 
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